Drug–drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition
- 14 November 2010
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 268 (6) , 530-539
- https://doi.org/10.1111/j.1365-2796.2010.02301.x
Abstract
The aim of this review is to discuss the effect of pharmacokinetic drug-drug interactions (DDIs) in the antiretroviral treatment of HIV infection. In particular, but not exclusively, DDIs due to the cytochrome P450 3A (CYP3A) inhibitor ritonavir, which is used to increase antiretroviral drug exposure - a technique known as pharmacokinetic enhancement or 'ritonavir boosting'- will be reviewed. The emphasis here will be on the treatment of important co-morbidities common in patients with HIV, including dyslipidaemia, hypertension, tuberculosis and opiate dependence, as well as on the potentially life-threatening interaction between ritonavir and inhalational steroids, and on the effect of acid-reducing agents on some antiretroviral drugs. Finally, further developments with regard to the use of CYP3A-blocking agents to augment the efficacy of antiviral therapy will be discussed.Keywords
This publication has 42 references indexed in Scilit:
- Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral MedicationsCurrent HIV/AIDS Reports, 2010
- Management of individuals requiring antiretroviral therapy and TB treatmentCurrent Opinion in HIV and AIDS, 2010
- A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R StudyClinical Infectious Diseases, 2009
- Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male VolunteersArchives of Drug Information, 2009
- Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug TransportAnesthesiology, 2009
- Lipid Management in Patients Who Have HIV and Are Receiving HIV TherapyEndocrinology and Metabolism Clinics of North America, 2009
- Cardiovascular Complications in HIV Management: Past, Present, and FutureJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsAIDS, 2008
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell lineJournal of Pharmaceutical Sciences, 2001